Resverlogix Presents ASSERT Human Clinical Trial Data at the American Heart Association Late Breaker Session
Chicago, November 17 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix") announces its top line results of the ASSERT Phase 2 clinical trial which will be highlighted at the prestigious American Heart Association Scientific Sessions 2010 Late Breaking Clinical Trial session, by principal investigator Dr. ...